Clinical Pharmacology of Recombinant Human Follicle-Stimulating Hormone. II. Single Doses and Steady State Pharmacokinetics

Recombinant follicle‐stimulating hormone (follitropin alfa) for ovulation induction in Japanese patients with anti‐estrogen‐ineffective oligo‐ or anovulatory infertility: results of a phase II dose–response study

“…Overall, there was a significant correlation between the r-hFSH dose group and the duration of dosing required to achieve a dominant follicle of C18 mm (primary endpoint), with dominant follicular growth achieved more rapidly in higher r-hFSH dose groups. No response to r-hFSH was observed in any group until after day 4; this is in keeping with the pharmacokinetic profile of r-hFSH, which takes 4 days to reach a steady state after daily subcutaneous administration of a consistent dose [14].…”

Serum inhibin B during controlled ovarian hyperstimulation: an additional criterion for deciding whether to proceed with egg retrieval

“…This hypothesis is in agreement with the results from Eldar-Geva et al (39), showing that the maximum increase of serum inhibin B concentrations under FSH treatment started at day 2 was reached by day 6 to 7 in normal responders and by day 4 to 5 in low responders. With regard to this study and those that consider the pharmacokinetics of rFSH (36,42), it seems that, in patients with normal response, the time-course of inhibin B is similar to the course of plasmatic FSH, the latter achieving its steady state 4-6 days after the first subcutaneous injection.…”

Lymphatic Transport of Proteins After Subcutaneous Administration

“…marily attributed to increased SBF measured by disappearance of 133 Xe from the subcutaneous tissue. A curvilinear relationship between SBF and the rate of disappearance of radiolabeled insulin was found and as a result, factors other than blood flow (i.e., depolymerization, interstitial diffusion, capillary permeability) were proposed as being rate limiting at high SBF.…”